CDK4 and breast cancer: Compared to tamoxifen, which is typically prescribed for pre-menopausal breast cancer patients, fulvestrant and AIs are mainly reserved for post-menopausal cases alone or in combination with other endocrine or targeted agents such as CDK4/6 inhibitors.